Article Text

Download PDFPDF
Turning the tide of high-dose inhaled corticosteroids

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The introduction of inhaled corticosteroids (ICS) proved to be a turning point in the management of asthma, and they remain the cornerstone of asthma treatment today.1,2 However, during the 1990s in the UK and Europe, there was a trend towards use of higher doses and this, coupled with the introduction of more potent ICS products, resulted in many people with asthma being prescribed high-dose ICS therapy, even though evidence of significant additional clinical benefit from this approach was limited.1 Although it was common for patients to be ‘stepped up’ to higher doses of ICS in line with national …

View Full Text